RS55815B1 - Kamsilatna so (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro[cikloheksan-1,2'-inden-1'2'-imidazol]-4"-amina i njene kristalne forme za tretman a[beta]-povezanih patologija poput, na primer, alzheimer-ove bolesti - Google Patents

Kamsilatna so (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro[cikloheksan-1,2'-inden-1'2'-imidazol]-4"-amina i njene kristalne forme za tretman a[beta]-povezanih patologija poput, na primer, alzheimer-ove bolesti

Info

Publication number
RS55815B1
RS55815B1 RS20170236A RSP20170236A RS55815B1 RS 55815 B1 RS55815 B1 RS 55815B1 RS 20170236 A RS20170236 A RS 20170236A RS P20170236 A RSP20170236 A RS P20170236A RS 55815 B1 RS55815 B1 RS 55815B1
Authority
RS
Serbia
Prior art keywords
disease
alzheimer
dementia
methyl
methoxy
Prior art date
Application number
RS20170236A
Other languages
English (en)
Serbian (sr)
Inventor
Martin Hans Bohlin
Craig Robert Stewart
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of RS55815B1 publication Critical patent/RS55815B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
RS20170236A 2012-06-21 2013-06-20 Kamsilatna so (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro[cikloheksan-1,2'-inden-1'2'-imidazol]-4"-amina i njene kristalne forme za tretman a[beta]-povezanih patologija poput, na primer, alzheimer-ove bolesti RS55815B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261662592P 2012-06-21 2012-06-21
PCT/GB2013/051606 WO2013190302A1 (en) 2012-06-21 2013-06-20 Camsylate salt
EP13733415.7A EP2864316B1 (en) 2012-06-21 2013-06-20 Camsylate salt of (1r,1'R,4R)- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin- 3-yl]-3'H-dispiro[cyclohexane-1,2'-inden-1'2'-imidazole]-4"-amine and crystalline forms thereof for the treatment of A[beta]-related pathologies such as e.g. Alzheimer's disease

Publications (1)

Publication Number Publication Date
RS55815B1 true RS55815B1 (sr) 2017-08-31

Family

ID=48746084

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20170236A RS55815B1 (sr) 2012-06-21 2013-06-20 Kamsilatna so (1r,1'r,4r)- 4-metoksi-5"-metil-6'-[5-(prop-1-in-1-il)piridin- 3-il]-3'h-dispiro[cikloheksan-1,2'-inden-1'2'-imidazol]-4"-amina i njene kristalne forme za tretman a[beta]-povezanih patologija poput, na primer, alzheimer-ove bolesti

Country Status (42)

Country Link
US (1) US10548882B2 (forum.php)
EP (2) EP2864316B1 (forum.php)
JP (2) JP2015520221A (forum.php)
KR (1) KR102123708B1 (forum.php)
CN (2) CN104411697B (forum.php)
AP (2) AP2014008137A0 (forum.php)
AR (2) AR091495A1 (forum.php)
AU (2) AU2013279109B2 (forum.php)
BR (2) BR112014031531B1 (forum.php)
CA (1) CA2875589C (forum.php)
CL (1) CL2014003374A1 (forum.php)
CO (1) CO7151486A2 (forum.php)
CR (2) CR20140571A (forum.php)
CY (1) CY1119505T1 (forum.php)
DK (1) DK2864316T3 (forum.php)
DO (1) DOP2014000268A (forum.php)
EC (1) ECSP14032215A (forum.php)
ES (1) ES2618939T3 (forum.php)
HR (1) HRP20170359T1 (forum.php)
HU (1) HUE033376T2 (forum.php)
IL (1) IL236131A0 (forum.php)
IN (1) IN2014DN10088A (forum.php)
LT (1) LT2864316T (forum.php)
MA (2) MA39259B1 (forum.php)
ME (1) ME02633B (forum.php)
MX (1) MX354214B (forum.php)
NI (1) NI201400146A (forum.php)
NZ (2) NZ702742A (forum.php)
PE (1) PE20150670A1 (forum.php)
PH (2) PH12014502803B1 (forum.php)
PL (1) PL2864316T3 (forum.php)
PT (1) PT2864316T (forum.php)
RS (1) RS55815B1 (forum.php)
RU (1) RU2638175C2 (forum.php)
SG (1) SG11201407934UA (forum.php)
SI (1) SI2864316T1 (forum.php)
SM (1) SMT201700142T1 (forum.php)
TN (1) TN2014000491A1 (forum.php)
TW (2) TWI639591B (forum.php)
UA (1) UA114196C2 (forum.php)
WO (1) WO2013190302A1 (forum.php)
ZA (1) ZA201500408B (forum.php)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9650336B2 (en) 2011-10-10 2017-05-16 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US10053453B2 (en) 2014-10-07 2018-08-21 Astrazeneca Ab Compounds and their use as BACE inhibitors
JP6546410B2 (ja) * 2015-02-23 2019-07-17 ローム株式会社 電力供給装置、acアダプタ、acチャージャ、電子機器および電力供給システム
AR107893A1 (es) * 2016-03-15 2018-06-28 Astrazeneca Ab TERAPIAS COMBINADAS, COMBINACIÓN DE UN INHIBIDOR DE BACE Y UN ANTICUERPO O UN FRAGMENTO DE UNIÓN AL ANTÍGENO PARA EL TRATAMIENTO DE UN TRASTORNO ASOCIADO CON LA ACUMULACIÓN DE b AMILOIDE
AR107783A1 (es) * 2016-03-15 2018-06-06 Lilly Co Eli Terapia de combinación
MX2021011105A (es) * 2019-03-14 2021-10-22 Astrazeneca Ab Lanabecestat para la perdida de peso.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100452491B1 (ko) * 2001-03-29 2004-10-12 한미약품 주식회사 신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
WO2002098462A1 (en) 2001-06-01 2002-12-12 Ono Pharmaceutical Co., Ltd. Remedies containing aldose reductase inhibitor as the active ingredient for demyelinating diseases or diseases associated with demyelination
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
ES2332184T3 (es) 2004-03-22 2010-01-28 ELI LILLY & COMPANY Derivados de piridilo y su uso como antagonistas del receptor mglu5.
CN101228163A (zh) 2005-06-14 2008-07-23 先灵公司 天冬氨酰蛋白酶抑制剂
WO2007058601A1 (en) 2005-11-21 2007-05-24 Astrazeneca Ab Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
EP1966163A1 (en) 2005-12-21 2008-09-10 Boehringer Ingelheim International GmbH Pyrimidine derivatives useful as inhibitors of pkc-theta
WO2007100536A1 (en) 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
EP2032542A2 (en) 2006-06-12 2009-03-11 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2008076043A1 (en) 2006-12-20 2008-06-26 Astrazeneca Ab Novel 2-amino-5,5-diaryl-imidazol-4-ones
US20090325993A1 (en) 2007-02-01 2009-12-31 Nadia Mamoona Ahmad GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders
CA2686589A1 (en) 2007-05-07 2008-11-13 Schering Corporation Gamma secretase modulators
WO2009100169A1 (en) 2008-02-06 2009-08-13 Glaxo Group Limited Dual pharmacophores - pde4-muscarinic antagonistics
FR2929943B1 (fr) * 2008-04-15 2010-09-24 Inst Rech Developpement Ird Sels de quinoleines 2-substituees
CN102105475B (zh) 2008-07-28 2014-04-09 卫材R&D管理有限公司 螺氨基二氢噻嗪衍生物
WO2010021680A2 (en) 2008-08-19 2010-02-25 Vitae Pharmaceuticals, Inc. Inhibitors of beta-secretase
CA2736130C (en) 2008-09-11 2014-01-14 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
KR101908255B1 (ko) 2009-03-13 2018-10-15 비타이 파마슈티컬즈, 인코포레이티드 베타세크리타아제 저해제
TW201105650A (en) 2009-07-02 2011-02-16 Astrazeneca Ab New compounds
UY32750A (es) 2009-07-02 2011-01-31 Astrazeneca Ab Imidazoles sustituidos y uso de los mismos
JP5828848B2 (ja) 2010-02-24 2015-12-09 ヴァイティー ファーマシューティカルズ,インコーポレイテッド ベータセクレターゼインヒビター
AR080865A1 (es) 2010-03-31 2012-05-16 Array Biopharma Inc Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
WO2011130741A1 (en) 2010-04-16 2011-10-20 Array Biopharma Inc. Compounds for treating neurodegenerative diseases
WO2012019056A1 (en) 2010-08-05 2012-02-09 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
AR083169A1 (es) 2010-09-24 2013-02-06 Array Biopharma Inc Compuestos para tratar enfermedades neurodegenerativas
US20120157448A1 (en) 2010-11-22 2012-06-21 Adam Cook Compounds for treating neurodegenerative diseases
US8415483B2 (en) 2010-12-22 2013-04-09 Astrazeneca Ab Compounds and their use as BACE inhibitors
US9650336B2 (en) 2011-10-10 2017-05-16 Astrazeneca Ab Mono-fluoro beta-secretase inhibitors
US9000185B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cycloalkyl ether compounds and their use as BACE inhibitors
US9000184B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
US9000182B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000183B2 (en) 2012-06-20 2015-04-07 Astrazeneca Ab Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors

Also Published As

Publication number Publication date
ME02633B (me) 2017-06-20
PT2864316T (pt) 2017-02-24
MA37666B1 (fr) 2016-12-30
JP2015520221A (ja) 2015-07-16
EP2864316B1 (en) 2016-12-14
IN2014DN10088A (forum.php) 2015-08-21
MX2014014709A (es) 2015-03-04
LT2864316T (lt) 2017-03-27
MA39259A1 (fr) 2017-12-29
TW201730177A (zh) 2017-09-01
AU2013279109B2 (en) 2017-08-31
EP3064494A1 (en) 2016-09-07
SG11201407934UA (en) 2015-01-29
BR122016014302A2 (pt) 2019-08-27
PH12016500498A1 (en) 2017-04-10
BR112014031531A2 (pt) 2017-06-27
CN104411697A (zh) 2015-03-11
CR20160202A (es) 2016-07-26
AR105176A2 (es) 2017-09-13
SMT201700142T1 (it) 2017-05-08
CA2875589C (en) 2020-08-25
SI2864316T1 (sl) 2017-04-26
DOP2014000268A (es) 2015-04-15
NZ702742A (en) 2016-12-23
IL236131A0 (en) 2015-02-01
BR122016014302B1 (pt) 2022-08-23
CL2014003374A1 (es) 2015-02-27
BR112014031531B1 (pt) 2022-08-02
ECSP14032215A (es) 2015-12-31
CN104411697B (zh) 2016-08-10
AU2017254965A1 (en) 2017-11-23
ES2618939T3 (es) 2017-06-22
CO7151486A2 (es) 2014-12-29
NZ727045A (en) 2018-06-29
RU2638175C2 (ru) 2017-12-12
PH12014502803A1 (en) 2015-02-23
KR20150023388A (ko) 2015-03-05
CY1119505T1 (el) 2018-03-07
MX354214B (es) 2018-02-19
ZA201500408B (en) 2016-10-26
JP2018104448A (ja) 2018-07-05
DK2864316T3 (en) 2017-03-20
AU2017254965B2 (en) 2019-05-09
HK1206349A1 (en) 2016-01-08
KR102123708B1 (ko) 2020-06-16
AP2014008137A0 (en) 2014-12-31
HRP20170359T1 (hr) 2017-05-05
EP2864316A1 (en) 2015-04-29
AU2013279109A1 (en) 2015-01-15
CA2875589A1 (en) 2013-12-27
MA37666A1 (fr) 2016-04-29
TN2014000491A1 (en) 2016-03-30
AP2017009693A0 (en) 2017-01-31
NI201400146A (es) 2016-09-21
PH12014502803B1 (en) 2015-02-23
PE20150670A1 (es) 2015-06-03
HUE033376T2 (en) 2017-11-28
TWI588140B (zh) 2017-06-21
AR091495A1 (es) 2015-02-11
PL2864316T3 (pl) 2017-09-29
UA114196C2 (uk) 2017-05-10
US10548882B2 (en) 2020-02-04
TWI639591B (zh) 2018-11-01
TW201406745A (zh) 2014-02-16
RU2014148305A (ru) 2016-08-10
US20140031379A1 (en) 2014-01-30
CR20140571A (es) 2015-02-04
JP6509393B2 (ja) 2019-05-08
WO2013190302A1 (en) 2013-12-27
MA39259B1 (fr) 2018-09-28
CN106279102A (zh) 2017-01-04

Similar Documents

Publication Publication Date Title
JP6509393B2 (ja) カンシル酸塩
EP2485736B1 (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US20070197509A1 (en) Compositions and methods for modulating gated ion channels
CA3103048A1 (en) Oga inhibitor compounds
CN104870000A (zh) 作为bace抑制剂的c5,c6氧杂环稠合的亚胺基噻嗪二氧化物化合物,组合物及其用途
US20170369484A1 (en) Iminothiadiazine dioxides bearing an amine-linked substituent as bace inhibitors, compositions, and their use
JP2011518225A (ja) Bace−1阻害剤としてのフェニル置換2−イミノ−3−メチルピロロピリミジノン化合物、組成物、およびそれらの使用
JP2016513092A (ja) 骨関節炎の処置のためのアグリカナーゼ阻害剤としての置換カルボン酸誘導体
CA2458388A1 (en) Novel benzothiazine derivatives, their preparation and use
HK1229787A1 (en) A process for the preparation of a camsylate salt ((1s)-(+)-10 camphorsulfonic acid) of (1r,1'r,4r)- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin- 3-yl]-3'h-dispiro[cyclohexane-1,2'-inden-1'2'-imidazole]-4"-amine
HK1206349B (en) Camsylate salt of (1r,1'r,4r)- 4-methoxy-5"-methyl-6'-[5-(prop-1-yn-1-yl)pyridin- 3-yl]-3'h-dispiro[cyclohexane-1,2'-inden-1'2'-imidazole]-4"-amine and crystalline forms thereof for the treatment of a[beta]-related pathologies such as e.g. alzheimer's disease
US20130245064A1 (en) Novel neurotrypsin inhibitors
MX2008007889A (en) Compositions and methods for modulating gated ion channels
AU2002333216A1 (en) Novel benzothiazine derivatives, their preparation and use